Efficacy and safety of sucroferric oxyhydroxide in the treatment of hyperphosphataemia in chronic kidney disease in Asturias. FOSFASTUR study J. Emilio Sanchez-Alvarez; Elena Astudillo Cortés; Miguel Seras Mozas; Raúl García Castro; Carlos Miguel Hidalgo Ordoñez; Ana Cristina Andrade López; Catalina Ulloa Clavijo; Anna Gallardo Pérez; Carmen Rodríguez Suarez;

Pharmacological nephrotoxicity profile in a comprehensive cancer center: What changed in two decades and predictors for the need for haemodialysis and mortality André Ferreira; Marina Reis; Teresa Chuva; Hugo Ferreira; Inês Coelho; Ana Paiva; José Maximino Costa;

Effectivity and safety profile of tenapanor, a sodium-hydrogen exchanger isoform 3 inhibitor, as an innovative treatment for hyperphosphatemia in chronic kidney disease: A systematic review of clinical studies William Suciangto; Haerani Rasyid; Anastasya Angelica Vicente; Winny Suciangto;